| Literature DB >> 6198913 |
M J Adams, G C Windham, L M James, F Greenberg, J A Clayton-Hopkins, C B Reimer, G P Oakley.
Abstract
Concentrations of maternal serum alpha-fetoprotein provide the basis for decisions to proceed to ultrasonography and amniocentesis in the multistaged screening/diagnostic process used for the prenatal detection of open neural tube defects, abdominal wall defects, and twins. The concentration of maternal serum alpha-fetoprotein at or above which women should be advised that amniocentesis is available (cutoff levels for amniocentesis) varies, depending upon a number of factors, such as maternal weight, race, residence, and gestational age. We briefly describe a methodology for computing the predicted risks of fetal conditions associated with a given concentration of maternal serum alpha-fetoprotein adjusted for important variables. This adjustment methodology provides a straightforward means for clinical laboratories to report results of assays of maternal serum alpha-fetoprotein in terms of predicted risks, to facilitate understanding by the physician and patient of the clinical meaning of the results of maternal serum alpha-fetoprotein testing.Entities:
Mesh:
Substances:
Year: 1984 PMID: 6198913 DOI: 10.1016/s0002-9378(84)80062-9
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN: 0002-9378 Impact factor: 8.661